319 related articles for article (PubMed ID: 8361261)
1. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint.
Legler UF
Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261
[TBL] [Abstract][Full Text] [Related]
2. Status of the GCP guidelines in Europe.
Geussenhainer S
Methods Find Exp Clin Pharmacol; 1993 May; 15(4):223-8. PubMed ID: 8361259
[TBL] [Abstract][Full Text] [Related]
3. The development of good clinical practice in the EEC and in Germany.
Anhalt E
Methods Find Exp Clin Pharmacol; 1993 May; 15(4):217-22. PubMed ID: 8361258
[TBL] [Abstract][Full Text] [Related]
4. [The GCP directive--consequences for clinical drug research].
Gluud CN
Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
[TBL] [Abstract][Full Text] [Related]
5. Experiences with GCP in the pharmaceutical industry [corrected].
Rämsch KD
Methods Find Exp Clin Pharmacol; 1993 May; 15(4):237-40. PubMed ID: 8240533
[TBL] [Abstract][Full Text] [Related]
6. [Quality assurance in clinical studies: a necessity].
Boll M; Binder J; Siegel A; Grundmann R
Z Exp Chir Transplant Kunstliche Organe; 1990; 23(2):65-72. PubMed ID: 2278157
[TBL] [Abstract][Full Text] [Related]
7. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
8. European Good Laboratory and Clinical Practices: their relevance to clinical pathology laboratories.
Dent NJ
Qual Assur; 1991 Oct; 1(1):82-8. PubMed ID: 1669972
[TBL] [Abstract][Full Text] [Related]
9. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
Englev E; Petersen KP
Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
[TBL] [Abstract][Full Text] [Related]
10. [Public GCP unit--experiences from the Aarhus University Hospital].
Jørgensen A; Rønnow IL; Nexø E
Ugeskr Laeger; 2003 Apr; 165(16):1667-9. PubMed ID: 12756826
[TBL] [Abstract][Full Text] [Related]
11. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
12. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
13. [Pharmaceutical aspects of clinical trials: concepts of pharmacokinetic investigations].
Czejka M
Onkologie; 2008; 31 Suppl 2():29-33. PubMed ID: 18487866
[TBL] [Abstract][Full Text] [Related]
14. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
Grienenberger A
J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
[TBL] [Abstract][Full Text] [Related]
15. [The roles and responsibilities of the pharmaceutical industry].
Dejgaard A; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1676-9. PubMed ID: 12756829
[TBL] [Abstract][Full Text] [Related]
16. Clinical quality assurance in the pharmaceutical industry.
Donahue JJ
Cancer Treat Rep; 1985 Oct; 69(10):1195-7. PubMed ID: 4042098
[No Abstract] [Full Text] [Related]
17. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
Lachin JM
Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
[TBL] [Abstract][Full Text] [Related]
18. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry].
Ebi O
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1883-91. PubMed ID: 9350232
[TBL] [Abstract][Full Text] [Related]
19. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
20. Drug development history, "overview," and what are GCPs?
Heilman RD
Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
